Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis


Kastritis E, Papassotiriou I, Terpos E, Roussou M, Gavriatopoulou M, Komitopoulou A, Skevaki C, Eleutherakis-Papaiakovou E, Pamboucas C, Psimenou E, et al. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. Blood [Internet]. 2016;128(3):405 - 409.


Cardiac dysfunction determines prognosis in amyloid light-chain (AL) amyloidosis. The heart is the central organ of the vascular system in which endothelium function is critical for the circulatory homeostasis, but there are limited data on endothelial function in AL amyloidosis. von Willebrand factor (VWF) has been considered as a marker of endothelial activation and dysfunction, whereas a disintegrin and metalloproteinase with thrombospondin type-1 repeats 13 (ADAMTS-13) cleaves VWF multimers, but both have been associated with prognosis in cardiovascular disease. We measured the serum levels of VWF (VWF:Ag) and ADAMTS-13 antigens in 111 newly diagnosed patients with AL amyloidosis. The levels of VWF:Ag were significantly higher than in healthy controls; 76% of patients with AL had VWF:Ag levels higher than the upper levels of controls. There was no significant association of VWF:Ag levels with patterns of organ involvement, free light-chain levels, the levels of cardiac biomarkers, or renal dysfunction but correlated with low systolic blood pressure. VWF:Ag levels ≥230.0 U/dL were associated with higher probability of early death and poor survival independently of cardiac biomarkers and low systolic blood pressure (SBP). Moreover, among patients with Mayo stage III or stage IIIB (that is stage III with N-terminal pro-brain natriuretic peptide [NTproBNP] >8500 pg/mL) disease, VWF:Ag identified subgroups of patients with very poor outcome. Low ADAMTS-13 levels correlated with high levels of NTproBNP but had no independent prognostic significance. In conclusion, high VWF:Ag levels, probably representing endothelial dysfunction, are associated with prognosis in patients with AL amyloidosis, independently of other features of the disease or cardiac biomarkers. © 2016 by The American Society of Hematology.


Export Date: 18 February 2017References: Merlini, G., Bellotti, V., Molecular mechanisms of amyloidosis (2003) N Engl J Med, 349 (6), pp. 583-596;Brenner, D.A., Jain, M., Pimentel, D.R., Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress (2004) Circ Res, 94 (8), pp. 1008-1010; Guan, J., Mishra, S., Qiu, Y., Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity (2015) EMBO Mol Med, 7 (5), p. 688; Liao, R., Jain, M., Teller, P., Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts (2001) Circulation, 104 (14), pp. 1594-1597; Mishra, S., Guan, J., Plovie, E., Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish (2013) Am J Physiol Heart Circ Physiol, 305 (1), pp. H95-H103; Shi, J., Guan, J., Jiang, B., Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway (2010) Proc Natl Acad Sci USA, 107 (9), pp. 4188-4193; Merlini, G., Comenzo, R.L., Seldin, D.C., Wechalekar, A., Gertz, M.A., Immunoglobulin light chain amyloidosis (2014) Expert Rev Hematol, 7 (1), pp. 143-156; Vita, J.A., Keaney, J.F., Jr., Endothelial function: A barometer for cardiovascular risk? (2002) Circulation, 106 (6), pp. 640-642; Berghoff, M., Kathpal, M., Khan, F., Skinner, M., Falk, R., Freeman, R., Endothelial dysfunction precedes C-fiber abnormalities in primary (AL) amyloidosis (2003) Ann Neurol, 53 (6), pp. 725-730; Franco, D.A., Truran, S., Burciu, C., Protective role of clusterin in preserving endothelial function in AL amyloidosis (2012) Atherosclerosis, 225 (1), pp. 220-223; Migrino, R.Q., Hari, P., Gutterman, D.D., Systemic and microvascular oxidative stress induced by light chain amyloidosis (2010) Int J Cardiol, 145 (1), pp. 67-68; Migrino, R.Q., Truran, S., Gutterman, D.D., Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins (2011) Am J Physiol Heart Circ Physiol, 301 (6), pp. H2305-H2312; Modesto, K.M., Dispenzieri, A., Gertz, M., Vascular abnormalities in primary amyloidosis (2007) Eur Heart J, 28 (8), pp. 1019-1024; Mannucci, P.M., Von Willebrand factor: A marker of endothelial damage? (1998) Arterioscler Thromb Vasc Biol, 18 (9), pp. 1359-1362; Meyer, A.A., Kundt, G., Steiner, M., Schuff-Werner, P., Kienast, W., Impaired flow-mediated vasodilation, carotid artery intima-media thickening, and elevated endothelial plasma markers in obese children: The impact of cardiovascular risk factors (2006) Pediatrics, 117 (5), pp. 1560-1567; La Mura, V., Reverter, J.C., Flores-Arroyo, A., Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension (2011) Gut, 60 (8), pp. 1133-1138; Kremer Hovinga, J.A., Lammle, B., Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura (2012) Hematol Am Soc Hematol Educ Program, 2012, pp. 610-616; Sonneveld, M.A., De Maat, M.P., Portegies, M.L., Low ADAMTS13 activity is associated with an increased risk of ischemic stroke (2015) Blood, 126 (25), pp. 2739-2746; Sonneveld, M.A., De Maat, M.P., Leebeek, F.W., Von Willebrand factor and ADAMTS13 in arterial thrombosis: A systematic review and meta-analysis (2014) Blood Rev, 28 (4), pp. 167-178; Rurali, E., Noris, M., Chianca, A., ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy (2013) Diabetes, 62 (10), pp. 3599-3609; Miura, M., Kaikita, K., Matsukawa, M., Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease (2010) Thromb Haemost, 103 (3), pp. 623-629; Freynhofer, M.K., Bruno, V., Jarai, R., Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation (2011) Thromb Haemost, 105 (3), pp. 435-443; Bongers, T.N., De Bruijne, E.L., Dippel, D.W., Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients (2009) Atherosclerosis, 207 (1), pp. 250-254; Gertz, M.A., Comenzo, R., Falk, R.H., Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004 (2005) Am J Hematol, 79 (4), pp. 319-328; Palladini, G., Dispenzieri, A., Gertz, M.A., New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes (2012) J Clin Oncol, 30 (36), pp. 4541-4549; Lip, G.Y., Blann, A., Von Willebrand factor: A marker of endothelial dysfunction in vascular disorders? (1997) Cardiovasc Res, 34 (2), pp. 255-265; Lenting, P.J., Casari, C., Christophe, O.D., Denis, C.V., Von Willebrand factor: The old, the new and the unknown (2012) J Thromb Haemost, 10 (12), pp. 2428-2437; Van Hinsbergh, V.W., Endothelium-role in regulation of coagulation and inflammation (2012) Semin Immunopathol, 34 (1), pp. 93-106; Freynhofer, M.K., Gruber, S.C., Bruno, V., Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation (2013) Int J Cardiol, 168 (1), pp. 317-325; Akiyama, E., Sugiyama, S., Matsuzawa, Y., Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction (2012) J Am Coll Cardiol, 60 (18), pp. 1778-1786; Kleber, M.E., Koller, L., Goliasch, G., Von Willebrand factor improves risk prediction in addition to N-terminal pro-B-type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction (2015) Circ Heart Fail, 8 (1), pp. 25-32; Paulus, W.J., Tschöpe, C., A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation (2013) J Am Coll Cardiol, 62 (4), pp. 263-271; Gertz, M.A., Dispenzieri, A., Sher, T., Pathophysiology and treatment of cardiac amyloidosis (2015) Nat Rev Cardiol, 12 (2), pp. 91-102; Borlaug, B.A., Olson, T.P., Lam, C.S., Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction (2010) J Am Coll Cardiol, 56 (11), pp. 845-854; Hivert, B., Caron, C., Petit, S., Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia (2012) Blood, 120 (16), pp. 3214-3221; Kastritis, E., Terpos, E., Papassotiriou, I., Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenstrom's Macroglobulinemia (2013) Blood, 122 (21), p. 1860; Mahmood, S., Riddle, A., Sachchithanantham, S., Bleeding diathesis and prothrombotic tendencies in patients with newly diagnosed systemic light chain Amyloidosis: Important clinical implications (2015) Clin Lymphoma Myeloma Leuk, 15, p. e201